Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 1/20 | 0.52 |
| ▸ | ERN1 | O75460 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | GRM5 | P41594 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27965841 | 0.86 | FFAR1 (0.55) | FFAR1ERN1GRM5 | |
| SCHEMBL30214468 | 0.79 | FFAR1 (0.58) | FFAR1ALDH1A1GRM5 | |
| SCHEMBL1809895 | 0.79 | FFAR1 (0.58) | FFAR1ALDH1A1GRM5 | |
| Hydrochloric Acid SCHEMBL19668206 | 0.77 | FFAR1 (0.57) | FFAR1ALDH1A1GRM5 | |
| SCHEMBL7868761 | 0.77 | FFAR1 (0.64) | FFAR1ERN1ALDH1A1 | |
| SCHEMBL28709978 | 0.77 | CASP3 (0.53) | FFAR1ERN1ALDH1A1GRM5 | |
| SCHEMBL352291 | 0.77 | GRM5 (0.65) | TDP1GRM5 | |
| SCHEMBL14061855 | 0.77 | GRM5 (0.53) | FFAR1ERN1GRM5 | |
| SCHEMBL5569770 | 0.77 | GRM5 (0.53) | FFAR1ERN1GRM5 | |
| SCHEMBL4750207 | 0.77 | FFAR1 (0.53) | FFAR1ERN1GRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140315857-A1 | N- (4 -QUINOLINYLMETHYL) SULFONAMIDE DERIVATIVES AND THEIR USE AS ANTHELMINTICS | E. I. DUPONT DE NEMOURS AND COMPANY | 2014-10-23 | — | — | US | disclosed |
| EP-2785694-A1 | N- (4 -QUINOLINYLMETHYL) SULFONAMIDE DERIVATIVES AND THEIR USE AS ANTHELMINTICS | E. I. Du Pont de Nemours and Company (US) | 2014-10-08 | — | — | EP | disclosed |
| WO-2013081783-A1 | N- (4 -QUINOLINYLMETHYL) SULFONAMIDE DERIVATIVES AND THEIR USE AS ANTHELMINTICS | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2013-06-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140315857-A1 | N- (4 -QUINOLINYLMETHYL) SULFONAMIDE DERIVATIVES AND THEIR USE AS ANTHELMINTICS | NQO2, SQOR, QSOX1 | FFAR1 2775/4885ERN1 3739/4885ALDH1A1 506/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.